MOHIT NARANG
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
- Where
- Eldersburg, MD
- NPI
- 1881695351
- Received
- $1,303,357 in 1,531 records, 2019 to 2025 ($1,291,941 general, $11,416 research)
- As principal investigator
- $3,421,426 of research payments to others in 1,291 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 350 | $290,678 |
| 2024 | General payment | 297 | $234,124 |
| 2023 | General payment | 268 | $196,200 |
| 2022 | General payment | 211 | $211,304 |
| 2021 | General payment | 134 | $154,257 |
| 2020 | General payment | 95 | $86,122 |
| 2019 | General payment | 174 | $119,254 |
| 2019 | Research payment | 2 | $11,416 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 272 | $782,598 |
| Consulting Fee | 118 | $227,813 |
| Travel and Lodging | 343 | $179,856 |
| Honoraria | 20 | $61,472 |
| Food and Beverage | 751 | $37,735 |
| Research payment | 2 | $11,416 |
| Long term medical supply or device loan | 14 | $1,248 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing | 1 | $750 |
| Education | 10 | $468 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-30 | E.R. Squibb & Sons, L.L.C. | $3,640 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-12-19 | ABBVIE INC. | $33 | Food and Beverage | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-12-17 | E.R. Squibb & Sons, L.L.C. | $1,110 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-12-17 | Novartis Pharmaceuticals Corporation | $27 | Food and Beverage | In-kind items and services | KISQALI Drug, Oncology | 2025 | |
| 2025-12-16 | Genmab U.S., Inc. | $30 | Food and Beverage | In-kind items and services | Epkinly Drug, Oncology | 2025 | |
| 2025-12-15 | PharmaEssentia USA Corporation | $385 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BESREMI Drug, Oncology | 2025 | |
| 2025-12-15 | Bayer Healthcare Pharmaceuticals Inc. | $343 | Consulting Fee | Cash or cash equivalent | Nubeqa Drug, Oncology | 2025 | |
| 2025-12-12 | Janssen Biotech, Inc. | $3,607 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-12-10 | Janssen Biotech, Inc. | $711 | Travel and Lodging | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-12-10 | E.R. Squibb & Sons, L.L.C. | $711 | Travel and Lodging | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-12-10 | E.R. Squibb & Sons, L.L.C. | $126 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-12-09 | Janssen Biotech, Inc. | $108 | Food and Beverage | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-12-09 | Merck Sharp & Dohme LLC | $30 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-12-09 | Corcept Therapeutics | $26 | Food and Beverage | In-kind items and services | Korlym Drug, Endocrinology | 2025 | |
| 2025-12-09 | Daiichi Sankyo Inc. | $25 | Food and Beverage | In-kind items and services | DATROWAY Drug, ONCOLOGY | 2025 | |
| 2025-12-03 | Merck Sharp & Dohme LLC | $32 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-12-02 | BeOne Medicines USA, Inc. | $4,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEVIMBRA Drug, Oncology | 2025 | |
| 2025-12-02 | BeOne Medicines USA, Inc. | $592 | Travel and Lodging | In-kind items and services | TEVIMBRA Drug, Oncology | 2025 | |
| 2025-12-02 | BeOne Medicines USA, Inc. | $149 | Food and Beverage | In-kind items and services | TEVIMBRA Drug, Oncology | 2025 | |
| 2025-12-02 | Bayer Healthcare Pharmaceuticals Inc. | $29 | Food and Beverage | In-kind items and services | Nubeqa Drug, Oncology | 2025 | |
| 2025-12-02 | Immunocore Limited | $21 | Food and Beverage | In-kind items and services | KIMMTRAK Drug, Oncology | 2025 | |
| 2025-11-26 | Lilly USA, LLC | $107 | Education | In-kind items and services | 2025 | ||
| 2025-11-25 | BeOne Medicines USA, Inc. | $34 | Food and Beverage | In-kind items and services | TEVIMBRA Drug, Oncology | 2025 | |
| 2025-11-21 | Janssen Biotech, Inc. | $5 | Travel and Lodging | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-11-19 | Janssen Biotech, Inc. | $555 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-11-14 | Bayer Healthcare Pharmaceuticals Inc. | $3,959 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Nubeqa Drug, Oncology | 2025 | |
| 2025-11-12 | Novartis Pharmaceuticals Corporation | $27 | Food and Beverage | In-kind items and services | PLUVICTO Drug, Oncology | 2025 | |
| 2025-11-11 | Merck Sharp & Dohme LLC | $30 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-11-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-10 | SANOFI US SERVICES INC. | $1,166 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-11-10 | Pharmacosmos Therapeutics Inc. | $171 | Food and Beverage | In-kind items and services | MONOFERRIC Drug, HEMATOLOGY | 2025 | |
| 2025-11-10 | PFIZER INC. | $23 | Food and Beverage | In-kind items and services | ELREXFIO Drug, ONCOLOGY | 2025 | |
| 2025-11-08 | AVYXA PHARMA, LLC | $2,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-11-08 | Bayer Healthcare Pharmaceuticals Inc. | $901 | Travel and Lodging | In-kind items and services | Nubeqa Drug, Oncology | 2025 | |
| 2025-11-08 | AVYXA PHARMA, LLC | $681 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-11-08 | AVYXA PHARMA, LLC | $638 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-11-08 | AVYXA PHARMA, LLC | $177 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-08 | AVYXA PHARMA, LLC | $105 | Travel and Lodging | In-kind items and services | 2025 | ||
| 2025-11-08 | AVYXA PHARMA, LLC | $89 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-07 | E.R. Squibb & Sons, L.L.C. | $21 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-11-06 | EMD Serono, Inc. | $25 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-11-05 | BeOne Medicines USA, Inc. | $4,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRUKINSA Drug, Oncology | 2025 | |
| 2025-11-05 | BeOne Medicines USA, Inc. | $418 | Travel and Lodging | In-kind items and services | BRUKINSA Drug, Oncology | 2025 | |
| 2025-11-05 | BeOne Medicines USA, Inc. | $327 | Travel and Lodging | In-kind items and services | BRUKINSA Drug, Oncology | 2025 | |
| 2025-11-04 | GENZYME CORPORATION | $2,016 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-11-04 | BeOne Medicines USA, Inc. | $139 | Food and Beverage | In-kind items and services | BRUKINSA Drug, Oncology | 2025 | |
| 2025-11-03 | E.R. Squibb & Sons, L.L.C. | $126 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-11-03 | Karyopharm Therapeutics Inc. | $48 | Food and Beverage | In-kind items and services | XPOVIO Drug, Oncology | 2025 | |
| 2025-10-30 | BeOne Medicines USA, Inc. | $6,400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRUKINSA Drug, Oncology | 2025 | |
| 2025-10-30 | BeOne Medicines USA, Inc. | $960 | Travel and Lodging | In-kind items and services | BRUKINSA Drug, Oncology | 2025 | |
| 2025-10-30 | BeOne Medicines USA, Inc. | $346 | Travel and Lodging | In-kind items and services | BRUKINSA Drug, Oncology | 2025 | |
| 2025-10-30 | BeOne Medicines USA, Inc. | $121 | Food and Beverage | In-kind items and services | BRUKINSA Drug, Oncology | 2025 | |
| 2025-10-30 | Novartis Pharmaceuticals Corporation | $24 | Food and Beverage | In-kind items and services | SCEMBLIX Drug, Oncology | 2025 | |
| 2025-10-29 | Genmab U.S., Inc. | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Epkinly Drug, Oncology | 2025 | |
| 2025-10-29 | GlaxoSmithKline, LLC. | $475 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OJJAARA Drug, ONCOLOGY | 2025 | |
| 2025-10-29 | Dendreon Pharmaceuticals LLC | $19 | Food and Beverage | In-kind items and services | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2025 | |
| 2025-10-28 | ABBVIE INC. | $33 | Food and Beverage | In-kind items and services | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-10-28 | Astellas Pharma US Inc | $26 | Food and Beverage | In-kind items and services | Padcev Drug, Oncology | 2025 | |
| 2025-10-27 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | EMRELIS Drug, ONCOLOGY | 2025 | |
| 2025-10-27 | Janssen Biotech, Inc. | $20 | Food and Beverage | In-kind items and services | ERLEADA Drug, Oncology | 2025 | |
| 2025-10-23 | BeOne Medicines USA, Inc. | $4,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEVIMBRA Drug, Oncology | 2025 | |
| 2025-10-23 | BeOne Medicines USA, Inc. | $536 | Travel and Lodging | In-kind items and services | TEVIMBRA Drug, Oncology | 2025 | |
| 2025-10-23 | BeOne Medicines USA, Inc. | $135 | Food and Beverage | In-kind items and services | TEVIMBRA Drug, Oncology | 2025 | |
| 2025-10-22 | Incyte Corporation | $24 | Food and Beverage | Cash or cash equivalent | JAKAFI Drug, Hematology/Oncology | 2025 | |
| 2025-10-17 | Regeneron Healthcare Solutions, Inc. | $4,704 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | 2025 | |
| 2025-10-17 | Regeneron Healthcare Solutions, Inc. | $772 | Travel and Lodging | In-kind items and services | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | 2025 | |
| 2025-10-16 | ABBVIE INC. | $2,100 | Consulting Fee | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-10-14 | Daiichi Sankyo Inc. | $24 | Food and Beverage | In-kind items and services | DATROWAY Drug, ONCOLOGY | 2025 | |
| 2025-10-14 | GlaxoSmithKline, LLC. | $15 | Food and Beverage | In-kind items and services | JEMPERLI Biological, ONCOLOGY | 2025 | |
| 2025-10-13 | Celgene Corporation | $33 | Food and Beverage | Cash or cash equivalent | BREYANZI Biological, Oncology | 2025 | |
| 2025-10-10 | Daiichi Sankyo Inc. | $29 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-10-08 | Janssen Biotech, Inc. | $278 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-10-08 | Aveo Pharmaceuticals, Inc. | $32 | Food and Beverage | In-kind items and services | FOTIVDA Drug, Oncology | 2025 | |
| 2025-10-07 | Janssen Biotech, Inc. | $1,110 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-10-07 | PFIZER INC. | $28 | Food and Beverage | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2025 | |
| 2025-10-07 | PFIZER INC. | $19 | Food and Beverage | In-kind items and services | PADCEV Biological, ONCOLOGY | 2025 | |
| 2025-09-30 | PharmaEssentia USA Corporation | $31 | Food and Beverage | In-kind items and services | BESREMI Drug, Oncology | 2025 | |
| 2025-09-30 | Azurity Pharmaceuticals, Inc. | $22 | Food and Beverage | In-kind items and services | DANZITEN Drug, ONCOLOGY | 2025 | |
| 2025-09-25 | Bayer Healthcare Pharmaceuticals Inc. | $343 | Consulting Fee | Cash or cash equivalent | Nubeqa Drug, Oncology | 2025 | |
| 2025-09-24 | Janssen Biotech, Inc. | $3,607 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-09-23 | Regeneron Healthcare Solutions, Inc. | $24 | Food and Beverage | In-kind items and services | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | 2025 | |
| 2025-09-22 | EMD Serono, Inc. | $22 | Food and Beverage | Cash or cash equivalent | 2025 | ||
| 2025-09-20 | ABBVIE INC. | $22 | Food and Beverage | In-kind items and services | IMBRUVICA Drug, ONCOLOGY | 2025 | |
| 2025-09-19 | Janssen Biotech, Inc. | $676 | Travel and Lodging | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-09-18 | Bayer Healthcare Pharmaceuticals Inc. | $3,350 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Nubeqa Drug, Oncology | 2025 | |
| 2025-09-18 | Janssen Biotech, Inc. | $150 | Food and Beverage | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-09-18 | Takeda Pharmaceuticals U.S.A., Inc. | $25 | Food and Beverage | In-kind items and services | VPRIV Biological, GENETIC DISEASE | 2025 | |
| 2025-09-18 | ACCORD HEALTHCARE, INC. | $23 | Food and Beverage | In-kind items and services | Camcevi Drug, Urology Oncology – GnRH agonist for treating adults with advanced prostate cancer | 2025 | |
| 2025-09-16 | Regeneron Healthcare Solutions, Inc. | $940 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | 2025 | |
| 2025-09-16 | Celgene Corporation | $33 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-09-16 | Caris MPI, Inc. | $30 | Food and Beverage | In-kind items and services | MI CANCER SEEK Device, ONCOLOGY | 2025 | |
| 2025-09-12 | BeOne Medicines USA, Inc. | $4,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRUKINSA Drug, Oncology | 2025 | |
| 2025-09-12 | BeOne Medicines USA, Inc. | $36 | Food and Beverage | In-kind items and services | BRUKINSA Drug, Oncology | 2025 | |
| 2025-09-11 | BeOne Medicines USA, Inc. | $7,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRUKINSA Drug, Oncology | 2025 | |
| 2025-09-11 | Bayer Healthcare Pharmaceuticals Inc. | $3,350 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Nubeqa Drug, Oncology | 2025 | |
| 2025-09-11 | BeOne Medicines USA, Inc. | $440 | Travel and Lodging | In-kind items and services | BRUKINSA Drug, Oncology | 2025 | |
| 2025-09-11 | BeOne Medicines USA, Inc. | $328 | Travel and Lodging | In-kind items and services | BRUKINSA Drug, Oncology | 2025 | |
| 2025-09-11 | BeOne Medicines USA, Inc. | $97 | Food and Beverage | In-kind items and services | BRUKINSA Drug, Oncology | 2025 | |
| 2025-09-11 | BeOne Medicines USA, Inc. | $0 | Travel and Lodging | In-kind items and services | BRUKINSA Drug, Oncology | 2025 | |
| 2025-09-09 | Novartis Pharmaceuticals Corporation | $27 | Food and Beverage | In-kind items and services | LUTATHERA Drug, Oncology | 2025 | |
| 2025-09-09 | Daiichi Sankyo Inc. | $14 | Food and Beverage | In-kind items and services | DATROWAY Drug, ONCOLOGY | 2025 | |
| 2025-09-09 | Novartis Pharmaceuticals Corporation | $1 | Food and Beverage | In-kind items and services | LUTATHERA Drug, Oncology | 2025 | |
| 2025-09-08 | Merck Sharp & Dohme LLC | $33 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2025 | |
| 2025-09-06 | Bayer Healthcare Pharmaceuticals Inc. | $611 | Travel and Lodging | In-kind items and services | Nubeqa Drug, Oncology | 2025 | |
| 2025-09-04 | Bayer Healthcare Pharmaceuticals Inc. | $3,350 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Nubeqa Drug, Oncology | 2025 | |
| 2025-09-04 | Bayer Healthcare Pharmaceuticals Inc. | $1,218 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Nubeqa Drug, Oncology | 2025 | |
| 2025-09-02 | E.R. Squibb & Sons, L.L.C. | $5,175 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-09-02 | Janssen Biotech, Inc. | $5 | Travel and Lodging | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-08-30 | Bayer Healthcare Pharmaceuticals Inc. | $547 | Travel and Lodging | In-kind items and services | Nubeqa Drug, Oncology | 2025 | |
| 2025-08-26 | Janssen Biotech, Inc. | $13 | Food and Beverage | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-08-22 | ABBVIE INC. | $2,400 | Consulting Fee | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | 2025 | |
| 2025-08-22 | E.R. Squibb & Sons, L.L.C. | $47 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-08-21 | E.R. Squibb & Sons, L.L.C. | $928 | Travel and Lodging | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-08-21 | E.R. Squibb & Sons, L.L.C. | $124 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-08-21 | Deciphera Pharmaceuticals Inc. | $14 | Food and Beverage | In-kind items and services | QINLOCK Drug, ONCOLOGY | 2025 | |
| 2025-08-20 | BeOne Medicines USA, Inc. | $4,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TEVIMBRA Drug, Oncology | 2025 | |
| 2025-08-20 | Janssen Biotech, Inc. | $1,110 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-08-20 | BeOne Medicines USA, Inc. | $565 | Travel and Lodging | In-kind items and services | TEVIMBRA Drug, Oncology | 2025 | |
| 2025-08-20 | BeOne Medicines USA, Inc. | $150 | Food and Beverage | In-kind items and services | TEVIMBRA Drug, Oncology | 2025 | |
| 2025-08-20 | Novartis Pharmaceuticals Corporation | $32 | Food and Beverage | In-kind items and services | PLUVICTO Drug, Oncology | 2025 | |
| 2025-08-20 | Novartis Pharmaceuticals Corporation | $32 | Food and Beverage | In-kind items and services | PLUVICTO Drug, Oncology | 2025 | |
| 2025-08-19 | Janssen Biotech, Inc. | $39 | Food and Beverage | In-kind items and services | TALVEY Biological, Oncology | 2025 | |
| 2025-08-19 | TerSera Therapeutics LLC | $23 | Food and Beverage | In-kind items and services | Zoladex Drug, Oncology | 2025 | |
| 2025-08-18 | PFIZER INC. | $24 | Food and Beverage | In-kind items and services | ELREXFIO Drug, ONCOLOGY | 2025 | |
| 2025-08-18 | Janssen Biotech, Inc. | $5 | Travel and Lodging | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-08-15 | E.R. Squibb & Sons, L.L.C. | $1,110 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-08-15 | Syndax Pharmaceuticals, Inc. | $34 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-08-14 | E.R. Squibb & Sons, L.L.C. | $5,175 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-08-14 | Stemline Therapeutics Inc. | $3,120 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Orserdu Drug, Oncology | 2025 | |
| 2025-08-14 | Stemline Therapeutics Inc. | $192 | Travel and Lodging | In-kind items and services | Orserdu Drug, Oncology | 2025 | |
| 2025-08-14 | Stemline Therapeutics Inc. | $117 | Food and Beverage | In-kind items and services | Orserdu Drug, Oncology | 2025 | |
| 2025-08-13 | Janssen Biotech, Inc. | $1,110 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-08-13 | Ipsen Biopharmaceuticals, Inc | $28 | Food and Beverage | In-kind items and services | Onivyde Drug, Oncology | 2025 | |
| 2025-08-12 | Bayer Healthcare Pharmaceuticals Inc. | $22 | Food and Beverage | In-kind items and services | Nubeqa Drug, Oncology | 2025 | |
| 2025-08-11 | AVYXA PHARMA, LLC | $82 | Food and Beverage | In-kind items and services | KYXATA Drug, ONCOLOGY | 2025 | |
| 2025-08-11 | PFIZER INC. | $25 | Food and Beverage | In-kind items and services | PADCEV Biological, ONCOLOGY | 2025 | |
| 2025-08-11 | Janssen Biotech, Inc. | $5 | Travel and Lodging | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-08-06 | Stemline Therapeutics Inc. | $68 | Food and Beverage | In-kind items and services | Orserdu Drug, Oncology | 2025 | |
| 2025-08-06 | Novartis Pharmaceuticals Corporation | $28 | Food and Beverage | In-kind items and services | LUTATHERA Drug, Oncology | 2025 | |
| 2025-08-05 | Stemline Therapeutics Inc. | $6,240 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Orserdu Drug, Oncology | 2025 | |
| 2025-08-05 | Stemline Therapeutics Inc. | $662 | Travel and Lodging | In-kind items and services | Orserdu Drug, Oncology | 2025 | |
| 2025-08-05 | Stemline Therapeutics Inc. | $460 | Travel and Lodging | In-kind items and services | Orserdu Drug, Oncology | 2025 | |
| 2025-08-05 | Stemline Therapeutics Inc. | $289 | Travel and Lodging | In-kind items and services | Orserdu Drug, Oncology | 2025 | |
| 2025-08-05 | Stemline Therapeutics Inc. | $109 | Food and Beverage | In-kind items and services | Orserdu Drug, Oncology | 2025 | |
| 2025-08-01 | SANOFI US SERVICES INC. | $437 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-07-31 | E.R. Squibb & Sons, L.L.C. | $941 | Travel and Lodging | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-07-31 | E.R. Squibb & Sons, L.L.C. | $94 | Food and Beverage | Cash or cash equivalent | REBLOZYL Biological, Hematology | 2025 | |
| 2025-07-30 | Genentech USA, Inc. | $18 | Food and Beverage | In-kind items and services | Polivy Biological, BioOncology | 2025 | |
| 2025-07-29 | Genentech USA, Inc. | $33 | Food and Beverage | In-kind items and services | Venclexta Biological, BioOncology | 2025 | |
| 2025-07-29 | Janssen Biotech, Inc. | $24 | Food and Beverage | In-kind items and services | TECVAYLI Biological, Oncology | 2025 | |
| 2025-07-25 | Regeneron Healthcare Solutions, Inc. | $29 | Food and Beverage | In-kind items and services | LYNOZYFIC Biological, HEMATOLOGY AND ONCOLOGY | 2025 | |
| 2025-07-24 | Janssen Biotech, Inc. | $2,875 | Consulting Fee | Cash or cash equivalent | DARZALEX Biological, Oncology | 2025 | |
| 2025-07-23 | Janssen Biotech, Inc. | $32 | Food and Beverage | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-07-22 | E.R. Squibb & Sons, L.L.C. | $455 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-07-22 | GENZYME CORPORATION | $145 | Food and Beverage | In-kind items and services | SARCLISA Biological, Oncology | 2025 | |
| 2025-07-22 | Regeneron Healthcare Solutions, Inc. | $29 | Food and Beverage | In-kind items and services | LIBTAYO Biological, ONCOLOGY | 2025 | |
| 2025-07-21 | E.R. Squibb & Sons, L.L.C. | $455 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-07-21 | E.R. Squibb & Sons, L.L.C. | $21 | Food and Beverage | Cash or cash equivalent | OPDIVO Biological, Oncology | 2025 | |
| 2025-07-18 | PFIZER INC. | $14 | Food and Beverage | In-kind items and services | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2025 | |
| 2025-07-15 | Janssen Biotech, Inc. | $3,607 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-07-15 | E.R. Squibb & Sons, L.L.C. | $455 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-07-14 | Janssen Biotech, Inc. | $618 | Travel and Lodging | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-07-10 | Janssen Biotech, Inc. | $130 | Food and Beverage | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-07-09 | PharmaEssentia USA Corporation | $221 | Travel and Lodging | Cash or cash equivalent | BESREMI Drug, Oncology | 2025 | |
| 2025-07-09 | PharmaEssentia USA Corporation | $39 | Travel and Lodging | Cash or cash equivalent | BESREMI Drug, Oncology | 2025 | |
| 2025-07-07 | E.R. Squibb & Sons, L.L.C. | $455 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-07-07 | E.R. Squibb & Sons, L.L.C. | $455 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-07-02 | PharmaEssentia USA Corporation | $4,060 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BESREMI Drug, Oncology | 2025 | |
| 2025-07-02 | Janssen Biotech, Inc. | $3,607 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-07-01 | Exelixis Inc. | $31 | Food and Beverage | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-06-30 | PharmaEssentia USA Corporation | $4,060 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BESREMI Drug, Oncology | 2025 | |
| 2025-06-30 | E.R. Squibb & Sons, L.L.C. | $31 | Food and Beverage | Cash or cash equivalent | ELIQUIS Drug, Cardiovascular | 2025 | |
| 2025-06-27 | Bayer Healthcare Pharmaceuticals Inc. | $1,218 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Nubeqa Drug, Oncology | 2025 | |
| 2025-06-27 | Novartis Pharmaceuticals Corporation | $29 | Food and Beverage | In-kind items and services | SCEMBLIX Drug, Oncology | 2025 | |
| 2025-06-27 | Novartis Pharmaceuticals Corporation | $0 | Food and Beverage | In-kind items and services | SCEMBLIX Drug, Oncology | 2025 | |
| 2025-06-26 | Exelixis Inc. | $2,500 | Honoraria | Cash or cash equivalent | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-06-26 | PharmaEssentia USA Corporation | $692 | Travel and Lodging | In-kind items and services | BESREMI Drug, Oncology | 2025 | |
| 2025-06-26 | PharmaEssentia USA Corporation | $198 | Travel and Lodging | In-kind items and services | BESREMI Drug, Oncology | 2025 | |
| 2025-06-26 | BeOne Medicines USA, Inc. | $149 | Food and Beverage | In-kind items and services | TEVIMBRA Drug, Oncology | 2025 | |
| 2025-06-26 | PharmaEssentia USA Corporation | $116 | Food and Beverage | In-kind items and services | BESREMI Drug, Oncology | 2025 | |
| 2025-06-25 | Incyte Corporation | $1,925 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-06-25 | Daiichi Sankyo Inc. | $29 | Food and Beverage | In-kind items and services | Enhertu Drug, ONCOLOGY | 2025 | |
| 2025-06-24 | Janssen Biotech, Inc. | $4,162 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RYBREVANT Drug, Oncology | 2025 | |
| 2025-06-24 | Dendreon Pharmaceuticals LLC | $26 | Food and Beverage | In-kind items and services | PROVENGE Drug, CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | 2025 | |
| 2025-06-24 | PFIZER INC. | $23 | Food and Beverage | In-kind items and services | PADCEV Biological, ONCOLOGY | 2025 | |
| 2025-06-24 | PFIZER INC. | $21 | Food and Beverage | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2025 | |
| 2025-06-23 | BeOne Medicines USA, Inc. | $2,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | BRUKINSA Drug, Oncology | 2025 | |
| 2025-06-23 | Janssen Biotech, Inc. | $576 | Travel and Lodging | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-06-23 | E.R. Squibb & Sons, L.L.C. | $455 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-06-21 | Exelixis Inc. | $286 | Travel and Lodging | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-06-21 | Exelixis Inc. | $286 | Travel and Lodging | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-06-21 | Exelixis Inc. | $90 | Food and Beverage | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-06-21 | Exelixis Inc. | $56 | Food and Beverage | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-06-21 | Exelixis Inc. | $30 | Food and Beverage | In-kind items and services | CABOMETYX Drug, Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | 2025 | |
| 2025-06-20 | Janssen Biotech, Inc. | $505 | Travel and Lodging | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-06-20 | Janssen Biotech, Inc. | $306 | Travel and Lodging | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-06-19 | Janssen Biotech, Inc. | $5 | Travel and Lodging | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-06-17 | PharmaEssentia USA Corporation | $669 | Travel and Lodging | In-kind items and services | BESREMI Drug, Oncology | 2025 | |
| 2025-06-17 | PharmaEssentia USA Corporation | $374 | Travel and Lodging | In-kind items and services | BESREMI Drug, Oncology | 2025 | |
| 2025-06-17 | PharmaEssentia USA Corporation | $224 | Travel and Lodging | In-kind items and services | BESREMI Drug, Oncology | 2025 |
The latest 200 records of 1,531.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-29 | Incyte Corporation | Maryland Oncology Hematology, P.a. | $4,500 | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita | 2025 |
| 2025-12-03 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $215 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-12-03 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $191 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-12-03 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $95 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-12-03 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $95 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-12-03 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $95 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-12-03 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $191 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-12-03 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $215 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-12-03 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $95 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-12-03 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $191 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-12-03 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $1,844 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-12-03 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $191 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-12-03 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $95 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-12-03 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $191 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-12-03 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $215 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-11-15 | Incyte Corporation | Maryland Oncology Hematology, P.a. | $1,600 | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita | 2025 |
| 2025-11-15 | Incyte Corporation | Maryland Oncology Hematology, P.a. | $1,600 | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita | 2025 |
| 2025-11-15 | Incyte Corporation | Maryland Oncology Hematology, P.a. | $1,600 | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita | 2025 |
| 2025-11-15 | Incyte Corporation | Maryland Oncology Hematology, P.a. | $1,600 | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita | 2025 |
| 2025-11-15 | Incyte Corporation | Maryland Oncology Hematology, P.a. | $1,600 | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita | 2025 |
| 2025-11-15 | Incyte Corporation | Maryland Oncology Hematology, P.a. | $200 | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita | 2025 |
| 2025-11-15 | Incyte Corporation | Maryland Oncology Hematology, P.a. | $1,600 | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita | 2025 |
| 2025-11-15 | Incyte Corporation | Maryland Oncology Hematology, P.a. | $1,600 | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita | 2025 |
| 2025-10-15 | Incyte Corporation | Maryland Oncology Hematology, P.a. | $956 | A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Pa | 2025 |
| 2025-10-15 | Incyte Corporation | Maryland Oncology Hematology, P.a. | $956 | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita | 2025 |
| 2025-10-15 | Celgene Corporation | Maryland Oncology Hematology, Pa | $5,851 | A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (Ibe | 2025 |
| 2025-10-02 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $215 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-10-02 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $191 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-10-02 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $191 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-10-02 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $95 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-10-02 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $191 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-10-02 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $1,844 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-10-02 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $215 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-10-02 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $215 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-10-02 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $215 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-10-02 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $2,516 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-10-02 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $1,844 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-10-02 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $191 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-10-02 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $191 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-10-02 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $215 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-10-02 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $95 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-10-02 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $215 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-10-02 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $95 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-09-30 | E.R. Squibb & Sons, L.L.C. | MARYLAND ONCOLOGY HEMATOLOGY COLUMBIA | $88 | A Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizum | 2025 |
| 2025-09-15 | Incyte Corporation | Maryland Oncology Hematology, P.a. | $125 | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita | 2025 |
| 2025-09-15 | Incyte Corporation | Maryland Oncology Hematology, P.a. | $1,600 | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita | 2025 |
| 2025-09-15 | Incyte Corporation | Maryland Oncology Hematology, P.a. | $1,600 | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita | 2025 |
| 2025-09-15 | Incyte Corporation | Maryland Oncology Hematology, P.a. | $1,600 | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita | 2025 |
| 2025-09-15 | Incyte Corporation | Maryland Oncology Hematology, P.a. | $100 | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita | 2025 |
| 2025-09-15 | Incyte Corporation | Maryland Oncology Hematology, P.a. | $1,600 | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita | 2025 |
| 2025-09-15 | Incyte Corporation | Maryland Oncology Hematology, P.a. | $666 | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita | 2025 |
| 2025-09-04 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $215 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-09-04 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $1,488 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-09-04 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $191 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-08-04 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $95 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-08-04 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $215 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-08-04 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $215 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-08-04 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $191 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-08-04 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $215 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-08-04 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $191 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-08-04 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $95 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-08-04 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $191 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-08-04 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $1,938 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-08-04 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $1,488 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-08-04 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $191 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-08-04 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $215 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-07-25 | Genmab U.S., Inc. | Maryland Oncology Hematology, P.a. | $1,000 | A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects Wit | 2025 |
| 2025-07-15 | Incyte Corporation | Maryland Oncology Hematology, P.a. | $956 | A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Pa | 2025 |
| 2025-07-15 | Incyte Corporation | Maryland Oncology Hematology, P.a. | $956 | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita | 2025 |
| 2025-07-03 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $191 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-07-03 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $62 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-07-03 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $2,516 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-07-03 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $4,997 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-07-03 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $1,479 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-07-03 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $215 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-07-03 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $95 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-06-20 | Celgene Corporation | SARAH CANNON RESEARCH INSTITUTE | $15,224 | A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (Ibe | 2025 |
| 2025-06-15 | Incyte Corporation | Maryland Oncology Hematology, P.a. | $476 | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita | 2025 |
| 2025-06-15 | Incyte Corporation | Maryland Oncology Hematology, P.a. | $125 | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita | 2025 |
| 2025-06-15 | Incyte Corporation | Maryland Oncology Hematology, P.a. | $125 | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita | 2025 |
| 2025-06-15 | Incyte Corporation | Maryland Oncology Hematology, P.a. | $476 | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita | 2025 |
| 2025-05-21 | Celgene Corporation | Maryland Oncology Hematology, Pa | $1,500 | Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Regist | 2025 |
| 2025-05-08 | Novocure Inc. | Us Oncology Research, Llc | $1,000 | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and | 2025 |
| 2025-04-15 | Incyte Corporation | Maryland Oncology Hematology, P.a. | $956 | A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Pa | 2025 |
| 2025-04-15 | Incyte Corporation | Maryland Oncology Hematology, P.a. | $956 | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita | 2025 |
| 2025-04-15 | Incyte Corporation | Maryland Oncology Hematology, P.a. | $956 | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita | 2025 |
| 2025-04-15 | Novocure Inc. | Maryland Oncology Hematology, P.a. | $850 | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and | 2025 |
| 2025-04-15 | E.R. Squibb & Sons, L.L.C. | Maryland Oncology Hematology, Pa | $1,310 | A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolum | 2025 |
| 2025-04-11 | Novocure Inc. | Us Oncology Research, Llc | $1,000 | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and | 2025 |
| 2025-03-26 | Hoffmann-La Roche Limited | Us Oncology Research, Llc | $1,125 | BLU667 1101 ARROW ongoing | 2025 |
| 2025-03-17 | E.R. Squibb & Sons, L.L.C. | Us Oncology Res Llc | $19,689 | A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolum | 2025 |
| 2025-03-15 | Incyte Corporation | Maryland Oncology Hematology, P.a. | $125 | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita | 2025 |
| 2025-03-15 | Incyte Corporation | Maryland Oncology Hematology, P.a. | $476 | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita | 2025 |
| 2025-03-15 | Incyte Corporation | Maryland Oncology Hematology, P.a. | $861 | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita | 2025 |
| 2025-03-15 | Incyte Corporation | Maryland Oncology Hematology, P.a. | $125 | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasita | 2025 |
| 2025-03-06 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $5,261 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
| 2025-02-07 | Hoffmann-La Roche Limited | Us Oncology Research, Llc | $235 | BLU667 1101 ARROW ongoing | 2025 |
| 2025-02-03 | Mirati Therapeutics, Inc. | Us Oncology Res Llc | $4,500 | Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 | 2025 |
| 2025-01-24 | Celgene Corporation | SARAH CANNON RESEARCH INSTITUTE | $20,400 | A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (Ibe | 2025 |
| 2025-01-20 | Karyopharm Therapeutics Inc. | MARYLAND ONCOLOGY HEMATOLOGY | $445 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | 2025 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Eldersburg, MD, county Carroll County, MD, state Maryland; placed by its city name.
| Measure | Place (city or town) Eldersburg, MD | County Carroll County, MD | State Maryland |
|---|---|---|---|
| Population B01003 | 31,695 | 175,321 | 6,206,011 |
| Population, 2020 census P1 | 32,582 | 172,891 | 6,177,224 |
| Median age B01002 | 39.0 | 41.3 | 39.4 |
| Under 18 B01001 | 24.3% | 22.0% | 22.2% |
| 65 and over B01001 | 15.5% | 17.9% | 16.7% |
| Households B11001 | 10,903 | 64,285 | 2,362,928 |
| Foreign born B05002 | 7.0% | 5.5% | 16.6% |
| Median household income B19013 | $142,954 | $118,211 | $103,678 |
| Median family income B19113 | $166,766 | $141,767 | $127,817 |
| Per capita income B19301 | $58,115 | $53,124 | $52,979 |
| Poverty rate B17001 | 4.7% | 5.2% | 9.4% |
| Unemployment rate B23025 | 3.1% | 3.5% | 4.9% |
| Civilian labor force B23025 | 16,932 | 95,243 | 3,313,651 |
| Mean commute (minutes) B08013 | 34.2 | 34.4 | 31.1 |
| Bachelor's degree or higher B15003 | 52.9% | 40.7% | 43.4% |
| Housing units B25001 | 11,183 | 66,768 | 2,560,784 |
| Owner-occupied B25003 | 88.0% | 84.3% | 67.6% |
| Renters B25003 | 12.0% | 15.7% | 32.4% |
| Median home value B25077 | $494,300 | $434,000 | $419,900 |
| Median gross rent B25064 | $1,705 | $1,427 | $1,705 |
| White, not Hispanic B03002 | 78.6% | 84.5% | 46.6% |
| Black B03002 | 6.1% | 4.0% | 28.9% |
| Hispanic or Latino B03002 | 5.7% | 5.1% | 12.5% |
| Asian B03002 | 4.0% | 2.4% | 6.5% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Eldersburg, MD.
Comments